(SRT3) Sartorius - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0007165631
SRT3: Bioprocess Equipment, Lab Products, Filtration Systems, Software
Sartorius Aktiengesellschaft is a global leader in bioprocess solutions and laboratory equipment, providing cutting-edge products and services to the life sciences industry. The company offers a comprehensive portfolio of bioreactors, including multi-parallel, benchtop, single-use, and stainless steel systems, as well as advanced software solutions for process control and data analysis. Sartorius also supplies cell culture media, microbiological testing kits, and fluid management products, catering to the needs of biopharmaceutical manufacturing, cell and gene therapy, and applied industries. Their product range extends to high-throughput screening, ultrafiltration solutions, and lab chromatography systems, ensuring a wide coverage of laboratory and industrial applications.
In addition to its product offerings, Sartorius provides a suite of services including contract manufacturing, OEM solutions, and process automation. The company’s expertise in bioprocess consulting and engineering, coupled with its commitment to innovation, positions it as a key player in the global life sciences market. Founded in 1870 and headquartered in Göttingen, Germany, Sartorius has established a strong reputation for quality and reliability, serving clients across the globe.
3-Month Forecast: Based on the providedAdditional Sources for SRT3 Stock
SRT3 Stock Overview
| Market Cap in USD | 15,993m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
SRT3 Stock Ratings
| Growth Rating | -30.3 |
| Fundamental | 14.4 |
| Dividend Rating | 23.7 |
| Rel. Strength | -22.2 |
| Analysts | - |
| Fair Price Momentum | 204.59 EUR |
| Fair Price DCF | 433.99 EUR |
SRT3 Dividends
| Dividend Yield 12m | 0.32% |
| Yield on Cost 5y | 0.29% |
| Annual Growth 5y | -7.11% |
| Payout Consistency | 94.4% |
SRT3 Growth Ratios
| Growth Correlation 3m | -86.5% |
| Growth Correlation 12m | -36% |
| Growth Correlation 5y | -61.4% |
| CAGR 5y | -1.98% |
| CAGR/Max DD 5y | -0.03 |
| Sharpe Ratio 12m | -1.13 |
| Alpha | -27.12 |
| Beta | 0.577 |
| Volatility | 50.17% |
| Current Volume | 105.9k |
| Average Volume 20d | 166.2k |
As of May 01, 2025, the stock is trading at EUR 228.00 with a total of 105,866 shares traded.
Over the past week, the price has changed by +3.45%, over one month by +6.74%, over three months by -17.47% and over the past year by -21.60%.
Neither. Based on ValueRay Fundamental Analyses, Sartorius is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SRT3 as of May 2025 is 204.59. This means that SRT3 is currently overvalued and has a potential downside of -10.27%.
Sartorius has no consensus analysts rating.
According to ValueRays Forecast Model, SRT3 Sartorius will be worth about 222.9 in May 2026. The stock is currently trading at 228.00. This means that the stock has a potential downside of -2.24%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 268 | 17.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 222.9 | -2.2% |